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Abstract
Background: Disease-specific biomarkers are an important tool for the timely and effective management of pathological
conditions, including determination of susceptibility, diagnosis, and monitoring efficacy of preventive or therapeutic
strategies. Aptamers, comprising single-stranded or double-stranded DNA or RNA, can serve as biomarkers of disease or
biological states. Aptamers can bind to specific epitopes on macromolecules by virtue of their three dimensional structures
and, much like antibodies, aptamers can be used to target specific epitopes on the basis of their molecular shape. The
Systematic Evolution of Ligands by EXponential enrichment (SELEX) is the approach used to select high affinity aptamers for
specific macromolecular targets from among the .10
13 oligomers comprising typical random oligomer libraries. In the
present study, we used live cell-based SELEX to identify DNA aptamers which recognize cell surface differences between
HPV-transformed cervical carcinoma cancer cells and isogenic, nontumorigenic, revertant cell lines.
Methodology/Principal Findings: Whole-cell SELEX methodology was adapted for use with adherent cell lines (which we
termed Adherent Cell-SELEX (AC-SELEX)). Using this approach, we identified high affinity aptamers (nanomolar range Kd)t o
epitopes specific to the cell surface of two nontumorigenic, nontumorigenic revertants derived from the human cervical
cancer HeLa cell line, and demonstrated the loss of these epitopes in another human papillomavirus transformed cervical
cancer cell line (SiHa). We also performed preliminary investigation of the aptamer epitopes and their binding
characteristics.
Conclusions/Significance: Using AC-SELEX we have generated several aptamers that have high affinity and specificity to
the nontumorigenic, revertant of HPV-transformed cervical cancer cells. These aptamers can be used to identify new
biomarkers that are related to carcinogenesis. Panels of aptamers, such as these may be useful in predicting the tumorigenic
potential and properties of cancer biopsies and aid in the effective management of pathological conditions (diagnosis,
predicted outcome, and treatment options).
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Introduction
Cervical cancer is the second most common cancer affecting
women worldwide [1]. More than 90% of cervical cancers are
caused by HPV, and approximately 10,800 new cases of HPV-
related cervical cancer are diagnosed in the United States (US)
annually [2]. More than 100 HPV types have been classified, the
most oncogenic of which are HPV16 and HPV18. HPV type 16
(HPV-16) is associated with more than 50% of cervical cancers
worldwide [3]. A recent study showed that HPV infection is also
associated with sexual activity and is the leading cause of the
increasing incidence of oropharyngeal cancer in the US [4]. Thus,
despite the availability of a preventive vaccine for HPV infection
[5], there remains a significant need for the development of
biomarkers that are specifically associated with HPV carcinogen-
esis rather than simply infection. These transformation specific
biomarkers would be useful for studies of disease progression,
prevention, and/or response to therapy. Here we describe the
development of an aptamer-based approach to identifying
biomarkers of HPV-mediated cell transformation.
The concept of aptamers arose through the observation that
macromolecules with different primary molecular structures will
each adopt a unique, three-dimensional configuration, each of
which will have unique affinities for binding to, and forming
complexes with other molecules [6]. It is in fact the same type of
sequence-dependent structural variations that is the basis for
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,20 years, the concept of structure-based binding has been
exploited to develop aptamer libraries, sets of macromolecules
with randomized sequences of nucleic acids (RNA or DNA).
Aptamer libraries are then screened for their ability to bind
preferentially to specific molecules or macromolecules using
SELEX (Systematic Evolution of Ligands by EXponential
enrichment), which combines aptamer enrichment through
iterative selection by affinity binding and polymerase chain
reaction (PCR), to discover high affinity, feature-specific double-
stranded or single-stranded RNA or DNA [6,7]. While aptamers
can have affinities comparable to those of monoclonal antibodies
they have several advantages. Aptamers can be produced in vitro
and hence do not require immunization, cell fusion, or
fermentation to produce mass quantities. Once the nucleic acid
sequence of a functional aptamer is determined, large quantities of
the specific oligomer can be produced by chemical or enzymatic
synthesis at low cost and high efficiency.
A more recent application is cell-SELEX, where aptamers that
recognize specific molecules on the surface of the cells are evolved
by repeated amplification and binding to living cells [8]. In this
approach aptamers can be used to identify a wide variety of
molecules including nucleic acids, proteins lipids, carbohydrates as
well as posttranslational modification of such molecules that are on
the surface of the exposed cells. Significantly, cell-SELEX offers
the unique ability to discover unknown or unidentified biomarkers
associated with a specific cell type, developmental stage, exposure,
infection, biological state or disease. Cell-SELEX has been
successfully utilized in non-adherent cell cultures to identify
aptamers which can recognize leukemia cells in biological
specimens [8,9]. In the present study we adapted whole cell-
SELEX for use on adherent cell lines (target and non-target), a
process which we termed Adherent Cell-SELEX (AC-SELEX) for
simplicity. Using AC-SELEX, we evolved aptamers that can
distinguish human papillomavirus (HPV)-transformed HeLa
cervical carcinoma cells from non-tumorigenic revertants of HeLa
cells (HF) that retain a functional, integrated HPV genome
[10,11]. The HF revertant cell line was previously derived in our
laboratory from HeLa cells exposed to a single mutagenic dose of,
ethylmethylsulfonate (EMS), followed by selection of clones from
cells that lost the prolonged Rhodamine 123 retention time
characteristic of most cancer cells [12]. Relative to the parental
HeLa cells, HF cells have a non-transformed phenotype,
decreased cloning efficiency in soft agar and are non-tumorigenic
in athymic nude mice [11]. HF6HeLa cell hybrid cells generated
by cell fusion showed significant reduction in cloning efficiency in
soft agar, suggesting the activation of a dominant tumor suppressor
gene in the HF cells and molecular analysis indicated reactivation
of the p53 tumor suppressor gene in HF cells, but without the loss,
rearrangement, or reduction in the expression of the HPV E6/E7
oncoproteins [10,11]. Given that HF cells are isogenic with HeLa
cells, differences in their gene expression patterns are likely to be
associated with loss of the tumorigenic phenotype, making this the
ideal cell pair in which to search for biomarkers of HPV-mediated
cell transformation.
Here we report on the discovery of single-stranded DNA
aptamers with high affinity for epitopes that are enriched on the
surface of the adherent, nontumorigenic HF cell line relative to the
tumorigenic HeLa cell line. The ability of the aptamers to detect
biomarkers lost during HPV-mediated cell transformation was
validated in the SiHa cervical carcinoma cell line. The results of
this study indicate that aptamers can be used to elucidate
candidate biomarkers for cellular changes associated with and/
or contributing to generation of a non-tumorigenic phenotype in
HPV-infected cells.
Results
Adherent Cell-SELEX and Identification of Target-Cell
Specific Aptamer Candidates
To adapt the whole cell-SELEX to adherent cells in culture, we
utlized the procedure outlined in Figure 1. Aptamers were targeted
to the nontumorigenic HF cell line, using isogenic HeLa cells for
negative counter-selection. After eighteen cycles of positive/
negative selection we identified molecular probes that were highly
specific for the revertant HF cell line (Table 1). We sequenced
eleven aptamer candidates and of these, four were randomly
chosen for further DNA sequence analysis and binding studies
(bold in Table 1). Since aptamers can be thought of as comprising
‘‘shape’’ libraries, we generated potential secondary structures for
each of the selected aptamers and calculated the relative free
energies for each of the predicted structures [13] (Figure 2).
Aptamer Binding Sites on the Target Cells
Once we obtained the nucleotide sequences for our target-cell
specific aptamers, the corresponding single-stranded DNA oligo-
nucleotides were synthesized with fluorescent FAM tags. The
labeled aptamers were then incubated with the HF cells to
determine the cellular localization of their binding sites (Figure 3).
The FAM conjugated aptamers were also incubated with the
parental HeLa cells to verify differential binding.
Confocal imaging and image reconstruction using z-stacks was
used to determine the cellular localization of aptamer-epitope
complexes (Figure 4). The binding sites of aptamers 13, 14, 20,
and 28 appeared to be located on the cell surface. Aptamer 14,
however, also appears to be binding to the perinuclear region
within the cell, which is consistent with binding of aptamer 14 to
epitopes on the cell surface followed by transport to the
perinuclear region. Although the mechanism by which this
oligomer entered the cell is unclear, pre-incubation of the HF
cells with proteinases (proteinase K or trypsin for 2 or 10 minutes
prior to aptamer binding) did not affect the ability of the cells to
internalize the FAM labeled aptamers. By contrast, proteinase
treatment significantly reduced the ability of aptamers 13, 20 and
28 to bind to the cells, suggesting that they were associated with
epitopes on cell surface proteins.
Aptamer Binding Characteristics
To determine the binding equilibrium of the aptamers to their
HF epitopes, we incubated HF cells with incremental concentra-
tions of the FAM tagged aptamers and measured the fluorescence
of individual cells (Figure 5). Based on our analysis, all aptamers
evaluated showed high affinity binding to their epitopes: Aptamer
13 (Kd=2.560.5 nM); Aptamer 14 (Kd=7.160.4 nM); aptamer
20 (Kd=1.660.4 nM); and Aptamer 28 (Kd=6.960.2 nM).
Aptamer Specificity for the Non-tumorigenic, HPV-
transformed Cervical Cancer Cell Line
To investigate whether the aptamers evolved for binding to non-
tumorigenic HF cells were recognizing cell-surface differences
specific to non-tumorigenic revertants, we also examined binding
to an independent clone of non-tumorigenic revertants of HeLa
cells (HA) and to another HPV-transformed cervical carcinoma
cell line (SiHa). Incubations of the FAM tagged aptamers with the
HA and SiHa cell lines (Figure 6) illustrated that the aptamers
specific for the non-transformed HF cells also bound to the HA
SELEX for Aptamer Probes of HPV-Associated Cancer
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These results indicated that the aptamers evolved against HF
revertant cells are specific for epitopes that were lost during HPV-
induced transformation of the cervical cells. Studies using the
aptamer reagents for affinity chromatography are in progress to
purify and identify the macromolecules harboring the epitopes.
Discussion
Highly sensitive and specific biomarkers are extremely useful for
diagnosis, treatment and prognosis of cancer cases. Cell-SELEX is
an in vitro procedure through which aptamers can be chosen by
their ability to bind differentially to cells [14], without any prior
knowledge of cellular changes. Aptamers can bind with high
Figure 1. Schematic of Adherent Cell-SELEX (AC-SELEX) Procedure. A starting library of .10
15 aptamers was utilized and eighteen rounds of
AC-SELEX were carried out to purify and amplify the aptamers which recognized epitopes present on HF cells and not present on HeLa cells. The
starting library was first incubated with the HeLa cell line and the unbound aptamers were recovered and utilized for the AC-SELEX procedure.
doi:10.1371/journal.pone.0036103.g001
Table 1. Aptamer sequences.
Aptamer ID Aptamer Sequences (random region)
10 59- GGGCAGGACTAGGGTAACGAGGTCGCATTTGGAGCAGGTG CAGGTGCGGTGT - 39
13 59 - GGGCACAGACGGAAGATGAGAATTGTGGGGCTTAGTATAG TGAGGTGCGTGT - 39
14 59 - GGGCGGGGAGTAGGGAGAGGGGTTTCCATCGGCGACAG AGGAGTTATGTGTGT - 39
17 59 - GGGGAGGGCGGTGATTAGAAGATTGCCTCTGATGAGGTAG GTCGGTGTGTGT - 39
20 59 - GGGGAGGGAGACACAGTCATGGAGCAGTTATTAGGGTGT ACCGGGTGTAGT - 39
21 59 - GGGGGGGAGAACGTAGTATGCATGGCGGTAATGAATGCTT GTAGTGCGTGGT - 39
24 59 - GGGGACAGGTAACAGGTGGGCAGTGTTGATCGGGGTGTTC GGTTTGCTGTGG - 39
26 59 - GGGGCGGAGTGGCTAGCGGGCAGCAAAAGGATGAGTCCCT GGAGTTATTGCC - 39
27 59 - GGGGAGCGGCTAGGATTGGGTGTGTGTAGCTGGATGAGGT CAATGTCGTGCT - 39
28 59 - GGGGGACACGGAGGTGGTGGAAAGGCTAAGATTTGATGAT GAGTAGTGTGGT - 39
29 59 - GGGGACGCGGGTGTACTAAGACAATTCAGTGCGATGGTAG TGGTGTGGCGGT - 39
All Aptamer sequences are flanked by the primer sequences: 59 – ATA CCA GCT TAT TCA ATT – N52 - AGA TAG TAA GTG CAA TCT – 39. Aptamers in bold were randomly
chosen for further characterization.
doi:10.1371/journal.pone.0036103.t001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e36103Figure 3. The target (HF) and non-target (HeLa) cell lines after incubation with FAM labeled aptamers. Images of HF and HeLa cells
incubated with fluorescently tagged aptamers. The aptamers are specific for the non-tumorigenic HF cell line. They recognize epitopes on or in the
HF cells and do not recognize their binding sites on the tumorigenic HeLa cells. All images are 406and are of cells within 24 hours after incubation
with 2000 nM aptamers and subsequent fixation and coverslipping with Aquamount.
doi:10.1371/journal.pone.0036103.g003
Figure 2. Predicted aptamer secondary structures. The secondary structures for each of the aptamers investigated. The structure(s) with the
lowest free energy (dG) are presented. Secondary structure predictions were determined using UNAfold software and are sir_graph H output [13].
doi:10.1371/journal.pone.0036103.g002
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offer a unique alternative to antibodies which are much larger,
easily degraded, costly and time-intensive to develop, and require
the use of animals [18]. Nucleic acid based-aptamers are easily
synthesized and can undergo reversible denaturation for PCR
amplification. They can also recognize small molecules like toxins
[19,20] and molecules that are not non-immunogenic complexes
[21] and aptamers can be easily modified with reporter molecules
or other molecules to enhance their properties (i.e. half life) [18].
Aptamers also adopt unique sequence-dependent three-dimen-
sional shapes, so they are in a sense, shape libraries and they may
bind to a cell based on their sequence, conformation and/or
charge through interactions with binding pockets, hydrogen
bonds, stacking of aromatic rings, van der Waals forces, or a
combination of these [22]. Aptamers can interfere with protein-
protein interactions, compete for and interfere with binding sites,
interfere with virus-cell attachment, transcription and mRNA
translation [23]. Owing to their small size, aptamers may also be
able to access epitopes that are normally blocked/hidden to other
probes/therapeutics. These desirable properties, afford aptamers
the ability to serve as therapeutic agents [21,24,25,26,27].
Aptamers are already being utilized in cancer biology and
cancer medicine [28,29,30]. Using cell-SELEX, investigators have
identified high affinity aptamers which increase the sensitivity of
pancreatic cancer to chemotherapeutics [31], deliver therapeutics
into cancer cells [32] or recognize cancer cells in biological
specimens [8,9]. SELEX has also enabled researchers to identify
aptamers which target transformation-specific antigens, such as
the HPV-16 E6 and E7 oncoproteins, in extracts of cervical cancer
cells [33,34]. Here we show that AC-SELEX can also be used to
identify cell surface markers that are altered during HPV-induced
cell transformation.
To evolve aptamers that differentiate HPV-transformed cells
from non-transformed cervical cell without a prior selection of
epitopes or targets, we adapted whole cell-SELEX for use on
adherent cell lines (Figure 1). Using this approach, we identified
and independently validated aptamers which have high affinity for
proteins or cell surface antigens that are specific to and present on
the surface of nontumorigenic revertants of HeLa cells, but are not
present on HPV transformed cervical carcinoma cell lines
(Figure 3). Importantly, two independently derived revertant cell
lines (HF and HA) continue to express the HPV E6 and E7
oncoproteins, but unlike the parental HeLa cells, the HF and HA
cell lines have a non-transformed morphology, contact inhibited
growth, significantly reduced cloning efficiency in soft agar, and
the inability to form tumors in nude mice [10,11]. In a single
screen, we were able to identify eleven unique aptamer sequences
that specifically recognize and bind to ligands present on the
nontransformed revertant HF cells, but not on the HeLa cells
(Table 1). Based on our results, aptamers 13, 20 and 28 bind to HF
specific cell surface epitopes, while aptamer 14 is binding to the
cell surface and being internalized into the cell cytoplasm
(Figure 4). The ability to abolish aptamer binding with
pretreatment of cells with protease suggested that three of the
Figure 4. Confocal images of aptamer-HF cell binding sites. Images of HF cells with FAM labeled aptamers. Aptamers 13, 20 and 28 appear to
be binding solely to the cell surfaces, while aptamer 14 is also being internalized into the cell cytoplasm. All images are 406and are of cells within
24 hours after incubation with 2000 nM aptamers and subsequent fixation and coverslipping with Aquamount.
doi:10.1371/journal.pone.0036103.g004
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Aptamer 14 was able to enter the cells independent of cell surface
protein binding, or was recognizing a protease resistant cell-
surface epitope that internalized the aptamer complex. Together
these findings indicated that AC-SELEX was able to evolve
aptamers that recognize changes in cell surface macromolecules
which distinguish the tumorigenic from non-tumorigenic HPV-
infected cells, suggesting utility as diagnostic probes.
To explore their prognostic potential, aptamers 13, 14, 20 and
28 were tested with an independent HPV-positive cervical cancer
cell line, SiHa, and an additional, non-tumorigenic revertant cell
line, HA. Significantly, we observed that the aptamers did
recognize their epitopes on non-tumorigenic HA cells, but did
not bind to the tumorigenic SiHa cells (Figure 6), supporting the
hypothesis that the aptamers recognize markers lost during HPV-
mediated transformation of cervical epithelial cells. Since the HF,
HA and HeLa cell lines are isogenic, we expect the differences in
gene expression not related to transformation to be minimal, and
therefore that the aptamers evolved are likely to recognize
important biomarkers and epitopes indicative of cervical cell
tumorigenicity. These results indicate that aptamers generated by
AC-SELEX have the ability to preferentially recognize highly
tumorigenic cervical cancer cell lines relative to non-tumorigenic
cervical cancer cell line revertants.
In summary, the present study demonstrated the feasibility of
Adherent Cell-SELEX as well as its utility in detecting epitopes
that are lost as a result of transformation of cervical epithelial cells
by HPV. Panels of aptamers such as these, evolved against
different tumor cell lines to distinguish cancer types and subtypes
may be useful used to relate diagnosis and prognosis and to
determine chemotherapy and disease susceptibility (i.e. genetic
differences).
Materials and Methods
Cell Culture
The early passage ATCC CCL2 clone of Hela cells as well as
the SiHa cervical carcinoma cell line were obtained from the
American Type Culture Collection. HF and HA cells were
obtained from experiments performed previously in which
selection of nontransformed revertants was obtained based on
the loss of rhodamine 123 from the cell mitochondria [11]. HeLa,
HF, HA and SiHa cells were cultured in Dulbecco’s Modified
Eagle Medium (Gibco) with 10% fetal bovine serum and 1%
penicillin-streptomycin solution.
SELEX Library and Primers
Single-stranded DNA sequences with 52 random nucleotides
flanked by known 18-nt primer sites were obtained from
Figure 5. Binding equilibrium for aptamers and their HF cell epitopes. Fluorescence quantification of FAM-labeled aptamers bound to HF
cells. Aptamer binding curves (line and data points) were generated by graphing the average fluorescence with the error bars representing the
standard error of the mean for each data point (n=4 per data point). These data were fitted to the model Y=Bmax*X(Kd+X) (solid line) which was
generated using nonlinear regression analysis for one site specific binding: aptamer 13 (Kd=2.560.5 nM); aptamer 14 (Kd=7.160.4 nM); aptamer 20
(Kd=1.660.4 nM); and aptamer 28 (Kd=6.960.2 nM).
doi:10.1371/journal.pone.0036103.g005
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ATACCAGCTTATTCAATT and 59-AGA TAG TAA GTG
CAA TCT. The FAM tagged primers were created as 59-FAM-
ATACCAGCTTATTCAATT and the biotin tagged primers
were created as 59-Biotin-AGATTGCACTTACTATCT.
SELEX Procedures
Before beginning, a starting library of approximately 1.6610
15
aptamers was incubated with the non-target HeLa cells and then
the unbound aptamers were recovered and prepared for the first
round of AC-SELEX. Prior to each round, aptamers were
denatured by heating at 95uC for 5 minutes and then briefly
cooled on ice for 2 minutes. For each round of incubations, 3610
5
HF cells were rinsed with PBS and incubated on ice with the
aptamer library in binding buffer (1% BSA in PBS with salts)
under gentle agitation. The cells were then rinsed with PBS and
the aptamers which bound to the HF cells were eluted through the
addition of the elution buffer (100 mM NaCl, 10 mM Tris 7.5,
1 mM EDTA and 1% SDS) and recovered using the Hirt DNA
prep method [35] which involved phenol extraction, phenol-
chloroform extraction, chloroform extraction. We also incorpo-
rated a back-extraction step to ensure adequate aptamer recovery.
The genomic DNA was then removed from the ethanol solution.
Aptamers were recovered from solution by ethanol precipitation
(3 M NaOAc in 100% ethanol) and allowed to settle overnight at
220uC. The resulting sample was then centrifuged and the pellet
rinsed twice with 70% ethanol and allowed to dry. The pellet was
then reconstituted in binding buffer and incubated with 10
6 HeLa
cells for aptamer counter-selection. The cells were then rinsed with
PBS and the nonbinding aptamers were recovered from this
rinsate again utilizing the Hirt method, including a back-
extraction step, followed by ethanol precipitation of aptamers.
The resulting aptamer libraries were then amplified via PCR with
a biotin-tagged primer and a non-biotin-tagged primer (Integrated
DNA Technologies), and the resulting double-stranded aptamers
were then separated using streptavidin coated beads and column
centrifugation to separate the unwanted biotin-tagged sequence
from the desired aptamer sequence (See PCR and Aptamer
Strand Separation). The resulting single-stranded aptamers
were then precipitated and used for the next round of AC-SELEX.
PCR and Aptamer Strand Separation
Aptamers resulting from the counter-selection step were
reconstituted with elution buffer (100 mM NaCl, 10 mM Tris
Figure 6. The nontumorigenic, HA and tumorigenic SiHa cervical cancer cells after aptamer incubation. Images depicting the non-
transformed revertant, HA cell line and the HPV-transformed cervical cancer cell line, SiHa, after incubation with FAM labeled aptamers. The aptamers
generated to target the non-transformed revertant, HF cell line also recognize the non-transformed revertant, HA cell line. Also notice that these
aptamers do not recognize epitopes on the SiHa cervical cancer cell line, similar to the results we observed with the HeLa cervical cancer cell line.
These results are consistent with the hypothesis that these aptamers are recognizing epitopes that are lost as a result of transformation of cervical
epithelial cells by HPV. All images are 406and are of cells within 24 hours after incubation with 2000 nM aptamers and subsequent fixation and
coverslipping with Aquamount.
doi:10.1371/journal.pone.0036103.g006
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biotin-tagged primers (94uC for 30 sec, 46uC for 30 sec, 72uC for
30 sec) on an Eppendorf-AG 22331 thermocycler (Hamburg,
Germany). The conditions for PCR amplification of aptamer
libraries differs from that of homogeneous DNA. PCR was
optimized around performing 18 rounds of AC-SELEX. Research
with a random nucleotide of this similar length has shown that
product formation reaches a maximum at 18 rounds and if more
than 20 rounds of PCR are performed, by-products begin to form
and there is a risk of complete loss of aptamer product [36]. The
resulting biotin-tagged double-stranded aptamers were then boiled
for 5 minutes, flash cooled in ice water for 3 minutes, and
incubated with streptavidin coated beads in column binding buffer
(20 mM NaPO4, 150 mM NaCl) prior to column centrifugation.
The resulting single-stranded aptamers were precipitated from the
column flow through via ethanol precipitation. The aptamer pellet
was then reconstituted in PBS with 1% BSA and this aptamer
solution was used for the next round of AC-SELEX.
Aptamer Cloning
After 18 rounds of AC-SELEX, the resulting aptamer pool was
PCR-amplified with unmodified primers. The resulting aptamer
library was then ligated into plasmids and cloned into Escherichia
coli using the TOPO TA cloning kit containing pCRH2.1-TOPOH
(Invitrogen, K4500-01). The plasmids were purified using QIAprep
Spin Miniprep (QIAGEN, 27106). The concentrations of the
resulting purified plasmids were determined using the Nanodrop
TM 1000 Spectrophotometer (Thermo Scientific). PCR followed
by gel electrophoresis was then performed on the purified plasmid
samples to ensure an insert of the proper length.
Aptamer Sequencing
Double stranded aptamers were sequenced using the M13
forward and reverse primers provided in the TOPO 10 Cloning
kit. Plasmids were sequenced by the University of Medicine and
Dentistry of New Jersey DNA Core Facility (Piscataway, NJ).
DNA Folding Predictions
The secondary structures of the single-stranded DNA aptamers
were predicted using UNAfold mfold software (http://mfold.rna.
albany.edu). The structures presented are output from sir_graph H
developed by D. Steward and M. Zuker [13].
Imaging of Cell-Aptamer Complexes
FAM 59-tagged aptamers were synthesized by Integrated DNA
Technologies. Cells were cultured in chamber slides, grown
overnight, rinsed with PBS and then allowed to incubate with the
fluorescently labeled aptamer(s) in PBS with 1% BSA on ice for
45 minutes. Cells were then rinsed with PBS prior to fixation with
4% paraformaldehyde. The fixed cells were then rinsed with PBS
and quickly with DNase free water and mounted using
Aquamount (Polysciences, Inc.). Cell-bound aptamers were then
imaged using a Leica confocal microscope.
Fluorescence Quantification Analysis
The fluorescence of the aptamer-cell complexes were measured
using Leica Lite software. Cells were imaged using a Leica
confocal microscope and individually quantified using Leica Lite
software. Four cells were quantified per data point after
background subtraction. The average fluorescence is graphed
with the error bars representing the standard error of the mean for
each data point. Apparent Kd values for each aptamer were
determined by nonlinear regression for on-site binding according
to the equation: Y=Bmax*X/(Kd+X) using GraphPad Prism
version 5.04 for Windows (GraphPad Software, La Jolla California
USA, www.graphpad.com [37].
Proteinase Treatment of Cells
We designed our AC-SELEX procedure to allow for aptamer
binding to surface protein epitopes which may be sensitive to
proteinases. In order to determine which aptamer epitopes were
sensitive to proteases, we treated the target cells with proteases a
minimum of 4 times for each proteinase and aptamer and
determined aptamer binding. Cells were treated with 0.05%
trypsin and 0.53 mM EDTA in HBSS or 0.1 mg/ml proteinase K
in PBS at 37uC for 2 and 10 min. The proteinase treated target
cells were then used for fluorescently labeled aptamer binding as
described above.
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